Early ADT for prostate cancer fails to improve survivalAndrogen deprivation therapy provides no survival benefit in older men with localized prostate cancer at 15 years, newly published research shows.Study findings, from Rutgers Cancer Institute ofRichard R. Kerr...
4. 2022 ESMO LBA9 - Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031) 审批号:VV-MEDMAT-78273 审批日期:2022...
[3] Carrie C, Magne N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up...
在欧洲患者亚组，与安慰剂 + ADT + 多西紫杉醇相比，达罗鲁胺 + ADT + 多西紫杉醇三联治疗改善了患者总生存率，死亡风险降低了37% (HR 0.63, 95% CI 0.48-0.83) ，4年生存率改善(61.6% VS 43.7%) ，与总体人群一致:与安慰剂 + ADT + 多西紫杉醇组相比，达罗他胺+ ADT + 多西紫杉醇组患者至...
[1] 2022 ESMO- LBA9 - Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031). [2] Mottet, N., et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Arnhem: European...
[1] 2022 ESMO- LBA9 - Duration of androgen deprivation therapy (ADT) with post-operative radiotherapy (RT) for prostate cancer: First results of the RADICALS-HD trial (ISRCTN40814031). [2] Mottet, N., et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Arnhem: European...
Esophageal squamous cell carcinoma (ESCC) is the predominant histologic subtype of esophageal cancer and characterized by high mortality rate and geographic differences in incidence. With the advances in the field of molecular biology, our understanding of the pathogenesis, epidemiology and behavior of ...
[4]Prostate Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. [5]Brown J E, Handforth C, Compston J E, et al. Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. Journal of Bone...
参考文献:Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol .Published online December 23, 2021 https://doi.org/10.1016/S0140...
[2]. 2021 AUA-PD08-09: Meta-analysis of radiation therapy and androgen deprivation therapy in localized prostate cancer. [3]. 2021 AUA-PD34-02: The key role of PSA doubling time in patients treated with salvage radiation therapy after radical prostatectomy: implications for the extent of radi...